Soliris approved to treat neuromyelitis optica spectrum disorder
(HealthDay)—The U.S. Food and Drug Administration has approved Soliris (eculizumab) injection as the first treatment for neuromyelitis optica spectrum disorder (NMOSD), the agency announced Thursday.
